Prevencio has been granted patents for its HART CADhs test in the USA—the second US patent for this novel test—as well as the EU and Japan. The patents protect Prevencio’s proprietary methods and algorithms for detecting obstructive coronary artery disease (CAD) using a multi-protein, artificial intelligence (AI)-driven blood test platform.
The newly issued patents strengthen Prevencio’s intellectual property portfolio and support its long-term strategy to expand HART CADhs adoption globally, the company says in a press release. HART CADhs is a blood test that combines multiple cardiac proteins with machine learning to deliver a highly accurate, non-invasive diagnosis of obstructive CAD.
“Securing patent protection in the USA, Europe, and Japan marks a major step forward in advancing our innovation and market leadership,” said Rhonda Rhyne, chief executive officer of Prevencio. “These patents reinforce the uniqueness of our HART CADhs test and underscore our commitment to improving cardiovascular diagnostics worldwide.”
“Cardiovascular disease is a global problem. International patent protection will help Prevencio to deliver scalable solutions that meet urgent diagnostic needs in the USA as well as global markets,” said James L Januzzi (Harvard Medical School, Boston, USA), chief scientific officer at the Baim Institute for Clinical Research and principal investigator for the HART test development and validation.
Prevencio’s HART blood tests are designed to improve accessibility, accuracy, and patient outcomes while reducing costs through earlier, more accessible, and accurate blood diagnostics, the company says in a press release. Both HART CADhs and HART CVE, a second AI-driven, multi-protein blood test that assesses a patient’s one-year risk of heart attack, stroke, or cardiovascular death, are currently available to healthcare providers and for research use.
